G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 26.2 PLN Market Closed
Market Cap: 34.6m PLN
Have any thoughts about
Genomed SA?
Write Note

Intrinsic Value

The intrinsic value of one GEN stock under the Base Case scenario is 25.53 PLN. Compared to the current market price of 26.2 PLN, Genomed SA is Overvalued by 3%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GEN Intrinsic Value
25.53 PLN
Overvaluation 3%
Intrinsic Value
Price
G
Worst Case
Base Case
Best Case

Valuation Backtest
Genomed SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GEN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GEN?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Genomed SA

Provide an overview of the primary business activities
of Genomed SA.

What unique competitive advantages
does Genomed SA hold over its rivals?

What risks and challenges
does Genomed SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Genomed SA.

Provide P/S
for Genomed SA.

Provide P/E
for Genomed SA.

Provide P/OCF
for Genomed SA.

Provide P/FCFE
for Genomed SA.

Provide P/B
for Genomed SA.

Provide EV/S
for Genomed SA.

Provide EV/GP
for Genomed SA.

Provide EV/EBITDA
for Genomed SA.

Provide EV/EBIT
for Genomed SA.

Provide EV/OCF
for Genomed SA.

Provide EV/FCFF
for Genomed SA.

Provide EV/IC
for Genomed SA.

Compare the intrinsic valuations
of Genomed SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Genomed SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Genomed SA compared to its peers.

Compare the P/E ratios
of Genomed SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Genomed SA with its peers.

Analyze the financial leverage
of Genomed SA compared to its main competitors.

Show all profitability ratios
for Genomed SA.

Provide ROE
for Genomed SA.

Provide ROA
for Genomed SA.

Provide ROIC
for Genomed SA.

Provide ROCE
for Genomed SA.

Provide Gross Margin
for Genomed SA.

Provide Operating Margin
for Genomed SA.

Provide Net Margin
for Genomed SA.

Provide FCF Margin
for Genomed SA.

Show all solvency ratios
for Genomed SA.

Provide D/E Ratio
for Genomed SA.

Provide D/A Ratio
for Genomed SA.

Provide Interest Coverage Ratio
for Genomed SA.

Provide Altman Z-Score Ratio
for Genomed SA.

Provide Quick Ratio
for Genomed SA.

Provide Current Ratio
for Genomed SA.

Provide Cash Ratio
for Genomed SA.

What is the historical Revenue growth
over the last 5 years for Genomed SA?

What is the historical Net Income growth
over the last 5 years for Genomed SA?

What is the current Free Cash Flow
of Genomed SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Genomed SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Genomed SA

Current Assets 6.6m
Cash & Short-Term Investments 2.8m
Receivables 1.7m
Other Current Assets 2.1m
Non-Current Assets 4m
PP&E 2.5m
Intangibles 88.9k
Other Non-Current Assets 1.4m
Current Liabilities 999.3k
Other Current Liabilities 999.3k
Non-Current Liabilities 313.4k
Other Non-Current Liabilities 313.4k
Efficiency

Earnings Waterfall
Genomed SA

Revenue
22.1m PLN
Cost of Revenue
-12.4m PLN
Gross Profit
9.7m PLN
Operating Expenses
-8.8m PLN
Operating Income
913.4k PLN
Other Expenses
-324.7k PLN
Net Income
588.7k PLN

Free Cash Flow Analysis
Genomed SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GEN Profitability Score
Profitability Due Diligence

Genomed SA's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Year Average ROIC
Positive 3-Years Revenue Growth
Negative Free Cash Flow
50/100
Profitability
Score

Genomed SA's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

GEN Solvency Score
Solvency Due Diligence

Genomed SA's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Genomed SA's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GEN Price Targets Summary
Genomed SA

There are no price targets for GEN.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GEN?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for GEN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Genomed SA

Country

Poland

Industry

Biotechnology

Market Cap

34.6m PLN

Dividend Yield

0%

Description

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

Contact

WOJ. MAZOWIECKIE
Warsaw
ul. Ponczowa 12
+48226446019
www.genomed.pl

IPO

2011-05-30

Employees

-

Officers

See Also

Discover More
What is the Intrinsic Value of one GEN stock?

The intrinsic value of one GEN stock under the Base Case scenario is 25.53 PLN.

Is GEN stock undervalued or overvalued?

Compared to the current market price of 26.2 PLN, Genomed SA is Overvalued by 3%.

Back to Top